Early Alzheimer's detection has remained frustratingly inaccessible in rural and low-education communities worldwide, where traditional cognitive assessments often fail due to educational bias and limited healthcare infrastructure. This implementation study demonstrates how combining a brief cognitive test with a simple blood biomarker could democratize dementia screening across diverse populations. Researchers deployed the Memory and Executive Screening test alongside plasma phosphorylated tau217 measurement in elderly Chinese participants, many with limited formal education. The cognitive assessment used individualized scoring that adjusted for demographic factors, successfully identifying cognitive impairment in 12.4% of participants without educational bias. The plasma p-tau217 biomarker showed striking age-related patterns, with positivity rates climbing from 3.5% in those under 60 to 25.9% in participants over 70. Among those already showing cognitive decline, more than one-quarter tested positive for the tau protein associated with Alzheimer's pathology. This represents a significant advance in practical dementia screening methodology. Traditional Alzheimer's diagnosis relies heavily on expensive neuroimaging or invasive spinal fluid analysis, creating barriers for underserved populations. The fully automated blood test format makes large-scale community deployment feasible, while the education-adjusted cognitive scoring addresses a persistent limitation in global dementia assessment. However, the screening thresholds require validation through longitudinal tracking to confirm their predictive accuracy. The approach appears particularly valuable for identifying at-risk individuals who might benefit from emerging Alzheimer's treatments, assuming these therapies prove most effective when initiated before substantial cognitive decline occurs.